Top

Published in:

Open Access 01-06-2020 | Pathology | CANCER

Pathology-confirmed versus non pathology-confirmed cancer diagnoses: incidence, participant characteristics, and survival

Authors: Kimberly D. van der Willik, Liliana P. Rojas-Saunero, Jeremy A. Labrecque, M. Arfan Ikram, Sanne B. Schagen, Bruno H. Stricker, Rikje Ruiter

Published in: European Journal of Epidemiology | Issue 6/2020

Abstract

Cancer diagnoses which are not confirmed by pathology are often under-registered in cancer registries compared to pathology-confirmed diagnoses. It is unknown how many patients have a non pathology-confirmed cancer diagnosis, and whether their characteristics and survival differ from patients with a pathology-confirmed diagnosis. Participants from the prospective population-based Rotterdam Study were followed between 1989 and 2013 for the diagnosis of cancer. Cancer diagnoses were classified into pathology-confirmed versus non pathology-confirmed (i.e., based on imaging or tumour markers). We compared participant characteristics and the distribution of cancers at different sites. Furthermore, we investigated differences in overall survival using survival curves adjusted for age and sex. During a median (interquartile range) follow-up of 10.7 (6.3–15.9) years, 2698 out of 14,024 participants were diagnosed with cancer, of which 316 diagnoses (11.7%) were non pathology-confirmed. Participants with non pathology-confirmed diagnoses were older, more often women, and had a lower education. Most frequently non pathology-confirmed cancer sites included central nervous system (66.7%), hepato-pancreato-biliary (44.5%), and unknown primary origin (31.2%). Survival of participants with non pathology-confirmed diagnoses after 1 year was lower compared to survival of participants with pathology-confirmed diagnoses (32.6% vs. 63.4%; risk difference of 30.8% [95% CI 25.2%; 36.2%]). Pathological confirmation of cancer is related to participant characteristics and cancer site. Furthermore, participants with non pathology-confirmed diagnoses have worse survival than participants with pathology-confirmed diagnoses. Missing data on non pathology-confirmed diagnoses may result in underestimation of cancer incidence and in an overestimation of survival in cancer registries, and may introduce bias in aetiological research.

Available only for authorised users

Cancer Research UK Worldwide cancer statistics.

Berkel J. General practitioners and completeness of cancer registry. J Epidemiol Community Health. 1990;44:121–4.CrossRefPubMedCentralPubMed

Schouten LJ, Hoppener P, van den Brandt PA, Knottnerus JA, Jager JJ. Completeness of cancer registration in Limburg, The Netherlands. Int J Epidemiol. 1993;22:369–76.CrossRefPubMed

Yancik R, Wesley MN, Ries LAG, Havlik RJ, Edwards BK, Yates JW. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA. 2001;285:885–92.CrossRefPubMed

Worthington JL, Koroukian SM, Cooper GS. Examining the characteristics of unstaged colon and rectal cancer cases. Cancer Detect Prev. 2008;32:251–8.CrossRefPubMed

Merrill RM, Sloan A, Anderson AE, Ryker K. Unstaged cancer in the United States: a population-based study. BMC Cancer. 2011;11:402.CrossRefPubMedCentralPubMed

Bradley CJ, Lin C, Clement JP. Absence of cancer diagnosis and treatment in elderly medicaid-insured nursing home residents. JNCI. 2008;100:21–31.CrossRefPubMed

Klassen AC, Platz EA. What can geography tell us about prostate cancer? Am J Prev Med. 2006;30:S7–15.CrossRefPubMed

Koroukian SM, Xu F, Beaird H, Diaz M, Murray P, Rose JH. Complexity of care needs and unstaged cancer in elders: a population-based study. Cancer Detect Prev. 2007;31:199–206.CrossRefPubMedCentralPubMed

10.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.CrossRefPubMed

11.

Ikram MA, Brusselle GGO, Murad SD, van Duijn CM, Franco OH, Goedegebure A, et al. The Rotterdam Study: 2018 update on objectives, design and main results. Eur J Epidemiol. 2017;32:807–50.CrossRefPubMedCentralPubMed

12.

Engberink MF, Bakker SJ, Brink EJ, van Baak MA, van Rooij FJ, Hofman A, et al. Dietary acid load and risk of hypertension: the Rotterdam Study. Am J Clin Nutr. 2012;95:1438–44.CrossRefPubMed

13.

Diabetes mellitus. Report of a WHO study group. World Health Organization technical report series. 1985;727:1–113.

14.

Bos MJ, Koudstaal PJ, Hofman A, Ikram MA. Modifiable etiological factors and the burden of stroke from the Rotterdam Study: a population-based cohort study. PLoS Med. 2014;11:e1001634.CrossRefPubMedCentralPubMed

15.

Leening MJ, Kavousi M, Heeringa J, van Rooij FJ, Verkroost-van Heemst J, Deckers JW, et al. Methods of data collection and definitions of cardiac outcomes in the Rotterdam Study. Eur J Epidemiol. 2012;27:173–85.CrossRefPubMedCentralPubMed

16.

de Roos EW, Lahousse L, Verhamme KMC, Braunstahl GJ, Ikram MA, In ‘t Veen J, et al. Asthma and its comorbidities in middle-aged and older adults; the Rotterdam Study. Respir Med. 2018;139:6–12.CrossRefPubMed

17.

de Bruijn RF, Bos MJ, Portegies ML, Hofman A, Franco OH, Koudstaal PJ, et al. The potential for prevention of dementia across two decades: the prospective, population-based Rotterdam Study. BMC Med. 2015;13:132.CrossRefPubMedCentralPubMed

18.

Cole SR, Hernan MA. Adjusted survival curves with inverse probability weights. Comput Methods Programs Biomed. 2004;75:45–9.CrossRefPubMed

19.

Hernán MA, Robins JM. Causal inference. Boca Raton: Chapman & Hall; 2019.

20.

IBM Corp. IBM SPSS statistics for windows, Version 24.0. Armonk: IBM Corp.;2016.

21.

Therneau TM. A package for survival analysis in R. New York: Springer; 2005.

22.

Kassambara A. Survminer: drawing survival curves using ‘ggplot2’. New York: Springer; 2018.

23.

Hamaker ME, Hamelinck VC, van Munster BC, Bastiaannet E, Smorenburg CH, Achterberg WP, et al. Nonreferral of nursing home patients with suspected breast cancer. J Am Med Dir Assoc. 2012;13:464–9.CrossRefPubMed

24.

Desch CE, Penberthy L, Newschaffer CJ, Hillner BE, Whittemore M, McClish D, et al. Factors that determine the treatment for local and regional prostate cancer. Med Care. 1996;34:152–62.CrossRefPubMed

25.

van Spronsen DJ, Janssen-Heijnen ML, Breed WP, Coebergh JW. Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin’s disease and non-Hodgkin’s lymphoma, 1993–1996. Ann Hematol. 1999;78:315–9.CrossRefPubMed

26.

Verstegen NE, Lagerwaard FJ, Haasbeek CJA, Slotman BJ, Senan S. Outcomes of stereotactic ablative radiotherapy following a clinical diagnosis of stage I NSCLC: comparison with a contemporaneous cohort with pathologically proven disease. Radiother Oncol. 2011;101:250–4.CrossRefPubMed

27.

Varadhachary GR. Carcinoma of unknown primary origin. GCR. 2007;1:229–35.PubMedPubMedCentral

28.

Volpe A, Panzarella T, Rendon RA, Haider MA, Kondylis FI, Jewett MAS. The natural history of incidentally detected small renal masses. Cancer. 2004;100:738–45.CrossRefPubMed

29.

Shaikh T, Churilla TM, Murphy CT, Zaorsky NG, Haber A, Hallman MA, et al. Absence of pathological proof of cancer associated with improved outcomes in early-stage lung cancer. J Thorac Oncol. 2016;11:1112–20.CrossRefPubMedCentralPubMed

30.

van der Willik KD, Ruiter R, van Rooij FJA, Verkroost-van Heemst J, Hogewoning SJ, Timmermans K, et al. Ascertainment of cancer in longitudinal research: the concordance between the Rotterdam Study and the Netherlands Cancer Registry. Int J Cancer. 2019. https://doi.org/10.1002/ijc.32750.CrossRefPubMedPubMedCentral

31.

Althubaiti A. Information bias in health research: definition, pitfalls, and adjustment methods. J Multidiscip Healthc. 2016;9:211–7.CrossRefPubMedCentralPubMed

32.

Lahousse L, Maes B, Ziere G, Loth DW, Verlinden VJ, Zillikens MC, et al. Adverse outcomes of frailty in the elderly: the Rotterdam Study. Eur J Epidemiol. 2014;29:419–27.CrossRefPubMed

Title: Pathology-confirmed versus non pathology-confirmed cancer diagnoses: incidence, participant characteristics, and survival
Authors: Kimberly D. van der Willik
Liliana P. Rojas-Saunero
Jeremy A. Labrecque
M. Arfan Ikram
Sanne B. Schagen
Bruno H. Stricker
Rikje Ruiter
Publication date: 01-06-2020
Publisher: Springer Netherlands
Keyword: Pathology
Published in: European Journal of Epidemiology / Issue 6/2020
Print ISSN: 0393-2990
Electronic ISSN: 1573-7284
DOI: https://doi.org/10.1007/s10654-019-00592-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Pathology-confirmed versus non pathology-confirmed cancer diagnoses: incidence, participant characteristics, and survival

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2020

Good science is good science: we need specialists, not sects

Outdoor light at night at residences and breast cancer risk in Canada

Disease mapping of early- and late-stage cancer to monitor inequalities in early detection: a study of cutaneous malignant melanoma

Do we really need to invoke heroic measures for early SARS-CoV-2 outbreak detection?

Radiation risk of central nervous system tumors in the Life Span Study of atomic bomb survivors, 1958–2009

Soy intake and breast cancer risk: a prospective study of 300,000 Chinese women and a dose–response meta-analysis